Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5915_Библиотеки_им_академика_М_И_Перельмана
.pdf
170
D.H. Geroski and H.F. Edelhauser
https://t.me/med1917
References
Ahmed I, Patton TF (1985) Importance of the noncorneal absorption route in topical ophthalmic
drug delivery. Invest Ophthalmol Vis Sci 26:584–587
Ahmed I, Gokhale RD, Shah MV, Patton TF (1987) Physico-chemical determinants of drug difusion
across the conjunctive, sclera, and cornea. J Pharm Sci 76:583–586
Borcherding MS, Blacik LJ, Sittig RA, Bizzell JW, Breen M, Weinstein HG (1975) Proteoglycans
and collagen fibre organization in human corneoscleral tissue. Exp Eye Res 21:59–70
Cruysberg LPJ, Nuyts RM, Geroski DH, Koole LH, Hendrikse F, Edelhauser HF (2002) In vitro
human scleral permeability of fluorescein, methotrexate–fluorescein and rhodamine 6
the use of: coated coil as a new drug delivery system. J Ocul Pharmacol Ther 18:559–569
Cruysberg LPJ, Nuyts RMMA, Gilbert JA, Geroski DH, Hendricks F, Edelhauser HF (2005) In
vitro sustained human transscleral drug delivery of fluorescein labeled dexamethasone and
methotrexate with fibrin sealant. Curr Eye Res 30:653–660
Edwards A, Prausnitz MR (1998) A fiber matrix model of sclera and corneal stroma for drug
delivery to the eye. AIChE J 44:214–225
Ghate D, Brooks W, McCarey BE, Edelhauser HF (2007) Pharmacokinetics of intraocular drug
delivery by periocular injections using ocular flurophotometry. Invest Ophthalmol Vis Sci
48:2230–2237
Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM, Edelhauser HF (2003)
Transscleral permeability and intraocular concentration of cisplatin from a collagen matrix.
J Control Release 89:409–417
Jiang J, Geroski DH, Edelhauser HF, Prausnitz MR (2006) Measurement and Prediction of lateral
diffusion within human sclera. Invest Ophthalmol Vis Sci 47:3011–3016
Kau JC, Geroski DH, Edelhauser HF (2005) Trans-scleral permeability of fluorescent antibiotics.
J Ocul Pharmacol Ther 21:1–10
Kim ES, Dkurairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF
(2009) Human scleral diffusion of anticancer drugs from solution and nanoparticle formula-
tion. Pharm Res 26(5):1155–1161
Lang JC (1995) Ocular drug delivery conventional ocular formulations. Adv Drug Delivery Rev
16:39–43
Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF (2004) Drug delivery through the scleral: the
effects of thickness, hydration and sustained release systems. Exp Eye Res 78:599–607
Lee SJ, Kim ES, Geroski DH, McCarey BE, Edelhauser HF (2008a) Pharmacokinetics of
Intraocular drug delivery of Oregon Green 488® labeled triamcinolone by subtenon injection
using ocular fluorophotometry in rabbit eyes. Invest Ophthalmol Vis Sci 49:4506–4514
Lee SJ, Kim SJ, Kim ES, Geroski DH, McCarey BE, Edelhauser HF (2008b) Transscleral perme-
ability of Oregon Green 488®. J Ocul Pharmacol Ther 24:579–586
Maurice DM, Polgar J (1977) Diffusion across the sclera. Exp Eye Res 25:577–582
Miyazaki S, Tkeuchi S, Yokouchi C, Takada M (1984) Pluronic F-127 gels as a vehicle for topical
administration of anticancer agents. Chem Pharm Bull 32:4205–4208
Olsen TW, Edelhauser HF, Lim JI, Geroski DH (1995) Human scleral permeability: effects of age,
cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci
36:1893–1903
Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF (1998) Human sclera: thickness and surface
area. Am J Ophthalmol 125:237–241
Pardue MT, Gilbert JA, Hejny C, Geroski DH, Edelhauser HF (2004) Preservation of retinal func-
tion in rabbit after subconjunctival injection of Carboplatin in fibrin sealant. Retina
24:776–782
Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature
analysis for drug delivery to the eye. J Pharm Sci 87:1479–1488
Prausnitz MR, Edwards A, Noonan JS, Rudnick DE, Edelhauser HF, Geroski DH (1998)
Measurement and prediction of transient transport across sclera for drug delivery to the eye. Ind
Eng Chem Res 37:2903–2907
G and
171
7 Transscleral Drug Delivery
https://t.me/med1917
Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J,
Csaky KG (2006) A rabbit model for assessing the ocular barriers to the transscleral delivery
of triamcinolone acetonide. Exp Eye Res 82:479–487
Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF (1999) The effect of intraoc-
ular pressure on sclera permeability. Invest Ophthalmol Vis Sci 40:3054–3058
Sanborn GE, Anand R, Torti RE (1992) Sustained-release of ganciclovir theraph for treatment of
cytomegalovirus retinitis. Arch Ophthal 110:188–195
Shuler RK Jr, Dioguardi PK, Henjy C et
oligonucleotide. J Ocul Pharmacol Ther 20:159–168
Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF (2002)
Transscleral diffusion of carboplatin: an in
120:1069–1074
Tsui YJ, Dalgard C, Van Quill KR, Lee L, Grossniklaus HF, Edelhauser HF, Obrien JM (2008)
Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblas-
toma. Invest Ophthalmol Vis Sci 29:490–496
Van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM Jr, Grossniklaus HE, Edelhauser HF,
O’Brien JM (2005) Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic
murine retinoblastoma. Ophthalmology 112:1151–1158
Yu BG, Kwon IC, Kim YH, Han DK, Park KD, Han K, Jeong SY (1996) Development of a local
antibiotic delivery system using fibrin glue. J Control Release 39:65–70
al (2004) Scleral permeability of a small single-stranded
vitro and in vivo study. Arch Ophthalmol
Chapter 8
https://t.me/med1917
Suprachoroidal and Intrascleral Drug Delivery
Timothy W. Olsen and Brian C. Gilger
Abstract Local drug delivery to the eye minimizes systemic side effects and targets
specific ocular tissue. In preclinical studies, transscleral and suprachoroidal delivery
appear to achieve therapeutic drug tissue levels that target specific tissues, such as
the choroid and macula. These routes allow minimally invasive sustained delivery
of drugs to the ocular posterior segment while minimizing systemic drug levels and
the associated side effects.
8.1 Introduction
The suprachoroidal route of delivery as well as deep lamellar scleral delivery are
both recently described routes for delivery to the posterior pole of the eye (Einmahl
et al. 2002; Gilger et al. 2006; Olsen et al. 2006; Jiang et al. 2007, 2009). Access to
these anatomic areas has just recently been explored. Theoretically, this route of
delivery has some key advantages. First, the suprachoroidal space is a potential
space inside the eye. It does not interfere with the optical pathways as opposed to
intravitreal injections. Second, diffusional pathways and pharmacokinetics are
clearly different for suprachoroidal than for intravitreal injections. Diffusional
access to the choroidal stroma may have advantages, particularly if one is targeting
a disease of the choroid. An example might include selective drug delivery in uveitis
or in macular diseases that originate in the choroid or retinal pigment epithelium
(RPE), respectively. Drugs do not need to cross the internal limiting membrane of
the retina in order to gain access to the outer retina, photoreceptors, RPE, and choroid.
T.W. Olsen (*)
Department of Ophthalmology, Emory Eye Center, Emory University
School of Medicine, Atlanta, GA, USA
e-mail: tolsen@emory.edu
U.B. Kompella and H.F. Edelhauser (eds.), Drug Product Development for the Back of the Eye,
AAPS Advances in the Pharmaceutical Sciences Series 2, DOI 10.1007/978-1-4419-9920-7_8,
© American Association of Pharmaceutical Scientists, 2011
173
174
T.W. Olsen and B.C. Gilger
https://t.me/med1917
Third, drug diffusion from the suprachoroidal space avoids the barriers seen with
transscleral delivery; namely, restrictive kinetic barriers of the sclera that have been
demonstrated to increase with larger molecules (Olsen et al. 1995). Fourth, drug
diffusion from this space may actually target the RPE in a more direct manner. Fifth,
sustained release agents, formulations, or devices could optimize diffusional kinetics from this space (Gilger et al. 2006; Olsen et al. 2006). And finally, there may be
advantageous immune responses to this space with larger biologic or immunogenic
agents (Olsen et al. 2010). Perhaps this route of delivery will offer a unique avenue
for future routine injections that are safe and effective in targeting retinal and macular diseases, such as diabetic retinopathy, retinal degeneration, and age-related macular degeneration (AMD). Efficacious local delivery methodology combined with
low systemic levels represents a key concept in technology design.
8.2 Background
Posterior segment eye diseases are a common cause of blindness in ophthalmology,
both in humans as well as in veterinary medicine. The total amount or volume of
tissue in the posterior segment is quite small relative to other organ systems. For this
reason, local drug delivery has become a very active area of research in vision sciences (Geroski and Edelhauser 2000).
Two important issues are driving new discoveries and treatment options for posterior segment disease. First, newer and more potent, targeted therapies are evolving
specifically toward diseases of the posterior segment of the eye. One such remarkable therapy is the use of antivascular endothelial growth factor (anti-VEGF) agents
for the treatment of neovascular AMD (Brown et al. 2006; Rosenfeld et al. 2006;
Gragoudas et al. 2004). Importantly, these drugs are not given systemically. Instead,
they are delivered locally. Clearly, numerous potential therapies are transforming
management of posterior segment disease to a pharmacologic and pharmacotherapeutic era in ophthalmology. Larger biologic agents, with targeted therapeutic and
highly selective effects, are creating new challenges in delivery. Second, local delivery minimizes systemic side effects by taking advantage of the fact that we only
need to treat a small volume of tissue relative to the rest of the body. The eye is
approximately 1:1,000 of the total body volume, and the macula itself is proportionally small relative to the eye at 1:1,000 of the volume of the eye. Thus, local drug
delivery for macular disease targets a small amount of tissue and minimizes the
potential for collateral damage from systemic side effects. More potent and more
highly efficacious agents reduce the dosing requirements, and allow for smaller
quantitative amounts of drug.
Ophthalmology has long depended upon topical drug delivery for many diseases
of the anterior segment, where diffusional barriers are minimal and access to critical
tissues are simple and immediate. Topical drops have been used to treat anterior
segment disease by optimizing formulation of each specific medication. Many of
the key barrier issues in achieving therapeutic drug levels have been addressed, such
175
8 Suprachoroidal and Intrascleral Drug Delivery
https://t.me/med1917
as a drug’s ability to cross the corneal epithelial and endothelial barriers. Anterior
segment tissues that are readily accessible with topical therapy include the conjunctiva, cornea, iris, and even the ciliary body. For small molecules with optimized
formulations, achieving a therapeutic drug level in these key tissues has been
achieved using many different agents, compounds, and formulations.
8.3 Posterior Segment Delivery
Despite remarkable successes in treatment of anterior segment ophthalmic disease,
treatment of posterior segment disease is clearly more challenging. Limitations for
topical application of medications reaching significant therapeutic levels in the posterior pole, largely involves the aqueous humor fluid dynamics. Essentially, there is
a bulk flow of fluid that removes drugs applied topically from the eye before reaching posterior segment tissues. The crystalline lens is also a barrier to posterior diffusion of drug into the vitreous. The vitreous itself modifies diffusion in unexpected
ways that we do not yet fully understand and is likely to be highly dependent upon
the levels of vitreous syneresis. Additionally, there are barriers for entry of drugs
into the neurosensory retina; namely, the blood retinal barrier, the internal limiting
membrane, and the tight junctions formed between the RPE cells and retinal vascular
endothelium.
There are other ocular flow systems that are gaining interest as important barriers
to achieving local drug delivery. Specifically, the choroid and the choroidal blood
flow as well as lymphatic circulation (Robinson et al. 2006). The effects of the choroidal vasculature on drugs that diffuse through the sclera or on drugs that are inserted
or injected into the suprachoroidal space are now recognized as important determinants in the pharmacokinetics of the posterior segment. The rapid blood flow of the
choroidal circulation remains a poorly understood variable in the pharmacokinetics
in this region (Fig. 8.1). For this reason, fluid dynamics within the subretinal space
and suprachoroidal space are currently under intensive study. Other unknown variables that influence uveoscleral outflow include, but are not limited to, the role of
the vortex ampullae, the influence of the RPE, Bruch’s membrane, and several other
factors.
8.4 Transscleral and Intrascleral Drug Delivery
Transscleral diffusion for drug delivery to the retina and RPE drug delivery offers a
relatively safe and direct pathway to posterior segment tissues. The transscleral
route avoids entry through the outer tunic of the globe. From clinical experience, an
agent such as triamcinolone can be delivered to the ocular posterior segment using
a periocular injection into the subtenon’s location. Presumably, the effect on uveal
tissues and inflammation is mediated through simple diffusion of the corticosteroid
176
T.W. Olsen and B.C. Gilger
https://t.me/med1917
Fig. 8.1 An indocyanine green angiogram in the early transit phase of a rhesus macaque (Olsen),
demonstrating the normal retinal vasculature overlying a more complex choroidal blood supply. This
image demonstrates the extensive nature of the choroidal blood flow relative to the retinal
vasculature
compound through the sclera and into the uveal tissues. Conceivably, the mechanism
of drug transport into the eye could also occur via the systemic circulation or through
more complex diffusional kinetics such as trans-conjunctival mediated topical
delivery (i.e., serving as a depot for sustained topical release).
Earlier work (Maurice and Polgar 1977) demonstrated that molecules traverse
the sclera. Later in vitro studies of human cadaveric sclera mounted in Ussing chambers demonstrated that the molecular size of a compound and the scleral thickness
were key determinants of diffusion across the sclera chambers (Olsen et al. 1995).
Mean scleral thickness as well as total scleral surface areas from a series of eyebank
eyes helped determine the parameters of transscleral diffusion (Olsen et al. 1998).
For small molecules, diffusion is rapid through the sclera. However, for larger biologic agents, such as ranibizumab or bevacizumab, there are significant limitations
to the transscleral route and effective intraocular levels may be suboptimal.
Various animal studies have investigated transscleral barriers and parameters that
influence diffusional kinetics in various species (Gilger et al. 2005; Olsen et al.
2002). Looking specifically at delivery of cyclosporine to treat equine recurrent
uveitis (ERU), placement of a biodegradable, matrix-reservoir cyclosporine A (CsA)
implant has demonstrated the advantage of deep scleral implantation compared with
transscleral diffusion (Gilger et al. 2006).
177
8 Suprachoroidal and Intrascleral Drug Delivery
https://t.me/med1917
8.5 Suprachoroidal Drug Delivery
Evidence that direct access to the suprachoroidal space is possible was first described
by Einmahl et al. in 2002 using a rabbit model (2002). The authors used poly-ortho
ester as a sustained drug delivery system with a solid, olive-tipped cannulae into the
suprachoroidal space. They demonstrated that material was present in the suprachoroidal space for 3 weeks, yet there were pigment irregularities at the site of
injection. In 2006, the use of a flexible, fiberoptic microcannula to access the suprachoroidal space in the pig model was reported (Olsen et al. 2006). This cannula
(Fig. 8.2a, b) was originally used to access Schlemm’s canal for circumferential
viscodilation during canaloplasty surgery (Lewis et al. 2009).
By accessing the suprachoroidal space in 94 porcine eyes, the authors demonstrated safety, and sustained local delivery for 120 days with very low systemic drug
levels and few complications (Olsen et al. 2006). Pre and postinjection histology
demonstrated that the potential space of the suprachoroidal region returns to a normal configuration after a brief period of time (Fig. 8.3a, b). Also, using dye-casting
methods, the suprachoroidal space is rather extensive and has the capacity to expand
and accommodate a relatively large volume of material (Fig. 8.4). The pharmacologic data demonstrated sustained local tissue levels from the sustained release formulation of triamcinolone in the suprachoroidal space along with either very low or
undetectable systemic levels.
More recent studies have sought to determine the kinetics of larger biologic
agents; such as bevacizumab injections into the suprachoroidal space accessed using
the same flexible microcannula system. Clearly, intravitreal injections of both
ranibizumab and bevacizumab are effective. However, there are several theoretic
advantages to the suprachoroidal route. Specifically, the diffusion through the choroidal stroma and through a damaged Bruch’s membrane may offer more direct
delivery to the disease-affected tissue than diffusion across the neurosensory retina.
Early studies suggest a very different profile of drug kinetics comparing the intravitreal route (Fig.
ing at a large molecular weight biologic, such as bevacizumab. Preliminary data
(Fig. 8.7) indicate that large biologic proteins, such as bevacizumab, are rapidly
removed from the suprachoroidal space, especially when these agents are not optimally formulated for sustained release (Olsen et al. 2010). Early studies also demonstrate a significant difference in the immune response to these two routes of
administration. Intravitreal administration in the pig model of a human antibody
(bevacizumab) has shown a granulomatous reaction (both vasculitis and vitritis;
Fig. 8.8) in a small percentage of eyes injected intravitreally, as compared to a similar
dose injected into the suprachoroidal space with no resultant inflammation.
Technologies are also evolving to optimize the ease of accessing this space. The
use of either coated or hollow microneedles to access the deeper scleral tissues and
even gain local access to the suprachoroidal region have been evaluated (Choy et al.
2008; Jiang et al. 2006, 2007, 2009). In studies using cadaver canine and porcine eyes,
a single injection of liquid latex into the anterior suprachoroidal space accessed by a
small sclerotomy created 5–7 mm posterior to the superior limbus resulted in the
8.5) with the suprachoroidal route (Fig. 8.6), especially when look-
Fig. 8.2 (a) TOP image of the microcannulation system (iScience Interventional Inc. Menlo Park,
https://t.me/med1917
CA). The box houses a fiberoptic so that the tip of the device can be identified in the suprachoroidal
space. The syringe is for injecting viscous material through the cannula. (b) Bottom image demonstrates the relative size of the tip (bottom) along with the depth markers so that one can determine
how far the cannula is extended into the suprachoroidal space
179
8 Suprachoroidal and Intrascleral Drug Delivery
https://t.me/med1917
Fig. 8.3 Left, the histopathology of a porcine eye that demonstrates the separation of the suprachoroidal space immediately following an injection with a viscoelastic substance (double arrow-
head). Note that pigmented cells are present in the choroid as well as in the inner scleral
layers. Right, the histopathology at 1 month following a suprachoroidal injection with a
viscoelastic agent, demonstrating the return to more normal apposition of the choroid to the
sclera (white arrow)
Fig. 8.4 Temporal and nasal sections of a canine (a) and porcine (b) globe showing the suprachor-
oidal distribution of a single injection of latex, black and white images hightlight the distribution
within the globe (B&W), and “edges” function of Image J NIH software
180
T.W. Olsen and B.C. Gilger
https://t.me/med1917
Fig. 8.5 (100×) The arrow points to a fluorescent-labeled drug that is bound to an antibody (beva-
cizumab) following an intravitreal injection using a 30-G needle at the pars plana. Note how the
drug is layered within the vitreous, limited partially by the internal limiting membrane (inner
boundary) of the neurosensory retina
Fig. 8.6 (100×) The arrow points to a fluorescent-labeled drug that is bound to an antibody (beva-
cizumab) following a suprachoroidal injection using the micro-catheter (see Fig. 8.2). Note that the
drug seems to be most concentrated at the endothelial layer of the larger choroidal vessels (arrow
left) as well as at the level of the RPE-photoreceptors (arrow right)
Соседние файлы в папке Библиотека им академика М.И. Перельмана